

# Supplementary Materials

to

## Real-world treatment of patients newly diagnosed with chronic obstructive pulmonary disease: A German claims data analysis

Roland Buhl<sup>1</sup>

Thomas Wilke<sup>2</sup>

Nils Picker<sup>3</sup>

Olaf Schmidt<sup>4</sup>

Marlene Hechtner<sup>5</sup>

Anke Kondla<sup>5</sup>

Ulf Maywald<sup>6</sup>

Claus F. Vogelmeier<sup>7</sup>

<sup>1</sup> Pulmonary Department, Mainz University Hospital, Mainz, Germany;

<sup>2</sup> IPAM e.V., Wismar, Germany;

<sup>3</sup> Cytel Inc - Ingress-Health HWM GmbH, Wismar, Germany;

<sup>4</sup> Pulmonary group practice, Koblenz, Germany;


<sup>5</sup> Boehringer Ingelheim International GmbH, Ingelheim, Germany;

<sup>6</sup> AOK PLUS, Dresden, Germany;


<sup>7</sup> Department of Medicine, Pulmonary and Critical Care Medicine, Philipps University of Marburg (UMR), Member of the German Center for Lung Research (DZL), Marburg, Germany

## List of Supplementary Figures:

**Figure S1:** Proportion of patients who started inhaled maintenance therapy for COPD within the 1st year.



**Figure S2:** Share of COPD-related costs in total costs.



**Table S1:** ATC codes used to identify COPD-related treatments.

Medication class	Agents	ATC-Codes	Taken into account within the treatment pattern analysis
SABA	Salbutamol	R03AC02	No
	Terbutaline	R03AC03	
	Fenoterol	R03AC04; R03CC04	
	Reproterol	R03CC14; R03AC15	
LABA	Salmeterol	R03AC12	Yes
	Formoterol	R03AC13	
	Indacaterol	R03AC18	
	Olodaterol	R03AC19	
	Bambuterol	R03CC12	
	Clenbuterol	R03CC13	
LABA-combi	Clenbuterol, combinations	R03CC63	Yes

<b>Medication class</b>	<b>Agents</b>	<b>ATC-Codes</b>	<b>Taken into account within the treatment pattern analysis</b>
SABA-combi	Fenoterol and sodium cromoglycate	R03AK03	No
	Salbutamol and sodium cromoglycate	R03AK04	
	Reproterol and sodium cromoglycate	R03AK05	
ICS/LABA	Salmeterol and fluticasone	R03AK06; R03AK61	Yes
	Formoterol and budesonide	R03AK07; R03AK28; R03AK72	
	Formoterol and beclometasone	R03AK08; R03AK27; R03AK71	
	Vilanterol and fluticasone furoate	R03AK10	
	Formoterol and fluticasone	R03AK11	
SABA/SAMA	Fenoterol and ipratropium bromide	R03AL01	No
	Salbutamol and ipratropium bromide	R03AL02	
LABA/LAMA	Vilanterol and umeclidinium bromide	R03AL03	Yes
	Indacaterol and glycopyrronium bromide	R03AL04	
	Formoterol and acclidinium bromide	R03AL05	
	Olodaterol and tiotropium bromide	R03AL06	
ICS	Beclometasone	R03BA01; R01AD01	Yes
	Budesonide	R03BA02; R01AD05	
	Fluticasone	R03BA05; R01AD08	
SAMA	Ipratropium bromide	R03BB01; R01AX03	No
LAMA	Tiotropium bromide	R03BB04	Yes
	Acclidinium bromide	R03BB05	
	Glycopyrronium bromide	R03BB06	
	Umeclidinium	R03BB07	
LABA/LAMA/ICS	Glycopyrronium and formoterol and beclometasone	R03AL09	Yes
Methylxanthine	Theophylline	R03DA04	Yes
	Aminophylline	R03DA05	
PDE-4	Roflumilast	R03DX07	Yes

**Table S2: Charlson Comorbidity Score (CCI) and components.**

<b>Comorbidity</b>	<b>ICD-10 code</b>	<b>Charlson score</b>
Coronary artery disease	I20-, I21-, I22-, I23-, I24-, I25-	1
Congestive heart failure	I11-, I50-	1
Peripheral vascular disease	I73-, I74-, I77-	1
Cerebrovascular disease	G45-, G46-, I6-	1
Dementia	F00-, F01-, F02-, F03-, G30-	1
Chronic pulmonary disease	J4-, J6- w/o J67-, J68-, J69-	1
Connective tissue disorder	M05-, M06-, M07-, M08-, M3-	1
Peptic ulcer disease	K25-, K26-, K27-, K28-	1
Mild liver disease	B18-, K70-, K73-, K75-	1
Diabetes mellitus without complications	E109-, E119-, E129-, E139-, E149-	1
Hemiplegia	G81-, G82-	2
Moderate or severe renal disease	N17-, N18-, N19-	2
Diabetes mellitus with end-organ damage	E10-, E11-, E12-, E13-, E14-	2
Tumor without metastases, leukemia, lymphoma, multiple myeloma	C- w/o [No 16]	2
Moderate or severe liver disease	K72-, K74-, I85-	3
Metastatic solid tumor	C77-, C78-, C79-, C80-	6
AIDS	B20-, B21-, B22-, B23-, B24-	6
Age factor [excluded]	For each decade $\geq 50$ years of age, 1 point is added to the score	